Our experiences of preoperative chemo-radiotherapy for T4 primary rectal cancer

Harunobu Sato, Koutarou Maeda, Tsunekazu Hanai, Yoshikazu Koide, Hiroyuki Aoyama, Hiroshi Matsuoka, Hidetoshi Katsuno, Masuo Funahashi, Toshihisa Agata, Tomohito Noro, Katsuyuki Honda, Miho Shiota

研究成果: ジャーナルへの寄稿学術論文査読


We reviewed 7 cases of clinical record with preoperative chemo-radiotherapy to evaluate the clinical effectiveness of the chemo-radiotherapy for T4 rectal cancer. The preoperative radiation therapy consisted of 40-45 Gy delivered in fractions of 1.8-2.0 Gy per day, five days a week. A treatment of 5-fluorouracil, 500 mg/body per day intravenously, or oral UFT-E (300 mg/m2) with l-leucovorin (75 mg) per day, or oral S-1 (80 mg/m2) per day five days a week, was given during radiotherapy. Grade 1 or 2 adverse effects occurred in 3 patients during chemo-radiotherapy, but the completion of chemo-radiotherapy was achieved in all of the 7 patients. Tumor invasion identified by CT and MRI to other organs in the pelvis disappeared in four cases with complete or partial response after a month of chemo-radiotherapy. Although the other organs were also removed during surgery in 4 patients, curative surgery was performed in 5 patients. There was no histological invasion seen to other organs in 4 patients, and one patient had histological complete disappearance of tumor. Although complications after surgery were found in all of the patients, they were improved by conservative treatment. One of 4 patients with curative surgery had liver and local recurrence, but others survived without recurrence. Preoperative chemo-radiotherapy was expected to be a safe and effective treatment to improve the resection rate and prognosis for T4 rectal cancer.

ジャーナルGan to kagaku ryoho. Cancer & chemotherapy
出版ステータス出版済み - 11-2008

All Science Journal Classification (ASJC) codes

  • 腫瘍学
  • 癌研究


「Our experiences of preoperative chemo-radiotherapy for T4 primary rectal cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。